Aastrom Biosciences (ASTM) craters 32% out the gate after saying it plans to cut its staff and...


Aastrom Biosciences (ASTM) craters 32% out the gate after saying it plans to cut its staff and operating costs by 50%, and end Phase III trials of its ixmyelocel-T drug for patients with critical limb ischemia - when there is an sudden lack of blood flow to a limb - as it was unable to bring in a partner. Instead, Aastrom will focus on Phase 2b trials of ixCELL for treating dilated cardiomyopathy (heart muscle disease). (PR)

From other sites
Comments (2)
  • ipjjm992
    , contributor
    Comments (2) | Send Message
     
    Why the big selloff.? Smaller studies with lower costs and a shorter path to regulatory approval. That to me spells success. Buy, Buy, Buy.
    27 Mar 2013, 09:58 AM Reply Like
  • ipjjm992
    , contributor
    Comments (2) | Send Message
     
    Why the big selloff? Smaller studies with lower costs and a shorter path to regulatory approval, to me, spells success. Buy, Buy, Buy.
    27 Mar 2013, 10:12 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs